Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines

British Journal of Haematology

Volumn 170, Issue 6, 2015, Pages 837-846

  Toda, Takashi ^a   Watanabe, Mariko ^b   Kawato, Junji ^a   Kadin, Marshall E ^c   Higashihara, Masaaki ^b   Kunisada, Takao ^d   Umezawa, Kazuo ^e   Horie, Ryouichi ^b  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEIJI SEIKA KAISHA LTD   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; Brefeldin A; Classical Hodgkin lymphoma; STAT3

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; ANAPLASTIC LYMPHOMA KINASE; BREFELDIN A; CASPASE 3; CD30 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; PROTEIN TYROSINE KINASE;

ANAPLASTIC LYMPHOMA KINASE POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA CELL LINE; ARTICLE; CELL DISRUPTION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CLASSICAL HODGKIN LYMPHOMA CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GOLGI COMPLEX; KARPAS299 CELL LINE; KMH2 CELL LINE; L540 CELL LINE; LYMPHOMA CELL LINE; MTT ASSAY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; SUDHL1 CELL LINE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ADP-RIBOSYLATION FACTOR 1; ANTIGENS, CD30; BREFELDIN A; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GOLGI APPARATUS; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NF-KAPPA B; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 84940585104     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13508     Document Type: Article

References (26)

1. Agostinelli, C., Piccaluga, P.P., Went, P., Rossi, M., Gazzola, A., Righi, S., Sista, T., Campidelli, C., Zinzani, P.L., Falini, B. & Pileri, S.A. (2008) Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. Journal of Clinical Pathology, 61, 1160-1167.
2. Bai, R.Y., Ouyang, T., Miething, C., Morris, S.W., Peschel, C. & Duyster, J. (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 96, 4319-4327.
3. Casanova, J.E. (2007) Regulation of Arf activation: the Sec7 family of guanine nucleotide exchange factors. Traffic, 8, 1476-1485.
4. Drexler, H.G. & MacLeod, R.A. (2004) Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma. Leukemia, 18, 1569-1571.
5. Horie, R. & Watanabe, T. (1998) CD30: expression and function in health and disease. Seminars in Immunology, 10, 457-470.
6. Horie, R. & Watanabe, T. (2003) The biological basis of Hodgkin's lymphoma. Drug News & Perspectives, 16, 649-656.
7. Horie, R., Watanabe, T., Morishita, Y., Ito, K., Ishida, T., Kanegae, Y., Saito, I., Higashihara, M., Mori, S., Kadin, M.E. & Watanabe, T. (2002) Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene, 21, 2493-2503.
8. Horie, R., Watanabe, M., Ishida, T., Koiwa, T., Aizawa, S., Itoh, K., Higashihara, M., Kadin, M.E. & Watanabe, T. (2004) The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell, 5, 353-364.
9. Horie, R., Ishida, T., Maruyama-Nagai, M., Ito, K., Watanabe, M., Yoneyama, A., Higashihara, M., Kimura, S. & Watanabe, T. (2007) TRAF activation of C/EBPbeta (NF-IL6) via p38 MAPK induces HIV-1 gene expression in monocytes/macrophages. Microbes and Infection, 9, 721-728.
10. Johnson, S., Nguyen, V. & Coder, D. (2013) Assessment of cell viability. Current Protocols in Cytometry, Chapter 9, Unit 9.2.
11. Klausner, R.D., Donaldson, J.G. & Lippincott-Schwartz, J. (1992) Brefeldin A: insights into the control of membrane traffic and organelle structure. Journal of Cell Biology, 116, 1071-1080.
12. Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P.N., Wlodarski, P. & Wasik, M.A. (2007) Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene, 26, 813-821.
13. Mathas, S., Kreher, S., Meaburn, K.J., Johrens, K., Lamprecht, B., Assaf, C., Sterry, W., Kadin, M.E., Daibata, M., Joos, S., Hummel, M., Stein, H., Janz, M., Anagnostopoulos, I., Schrock, E., Misteli, T. & Dorken, B. (2009) Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 106, 5831-5836.
14. Medeiros, L.J. & Elenitoba-Johnson, K.S. (2007) Anaplastic Large Cell Lymphoma. American Journal of Clinical Pathology, 127, 707-722.
15. Mossessova, E., Gulbis, J.M. & Goldberg, J. (1998) Structure of the guanine nucleotide exchange factor Sec7 domain of human arno and analysis of the interaction with ARF GTPase. Cell, 92, 415-423.
16. Ohashi, Y., Iijima, H., Yamaotsu, N., Yamazaki, K., Sato, S., Okamura, M., Sugimoto, K., Dan, S., Hirono, S. & Yamori, T. (2012) AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy. Journal of Biological Chemistry, 287, 3885-3897.
17. Pan, H., Yu, J., Zhang, L., Carpenter, A., Zhu, H., Li, L., Ma, D. & Yuan, J. (2008) A novel small molecule regulator of guanine nucleotide exchange activity of the ADP-ribosylation factor and golgi membrane trafficking. Journal of Biological Chemistry, 283, 31087-31096.
18. Saenz, J.B., Sun, W.J., Chang, J.W., Li, J., Bursulaya, B., Gray, N.S. & Haslam, D.B. (2009) Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. Nature Chemical Biology, 5, 157-165.
19. Stein, H., Foss, H.D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., Pileri, S. & Falini, B. (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood, 96, 3681-3695.
20. Su, I.J. & Kadin, M.E. (1989) Expression of growth factor/receptor genes in postthymic T cell malignancies. American Journal of Pathology, 135, 439-445.
21. Takeiri, M., Ota, E., Nishiyama, S., Kiyota, H. & Umezawa, K. (2012) Structure-activity relationship of 9-methylstreptimidone, a compound that induces apoptosis selectively in adult T-cell leukemia cells. Oncology Research, 20, 7-14.
22. Viaud, J., Zeghouf, M., Barelli, H., Zeeh, J.C., Padilla, A., Guibert, B., Chardin, P., Royer, C.A., Cherfils, J. & Chavanieu, A. (2007) Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein-protein complexes. Proceedings of the National Academy of Sciences of the United States of America, 104, 10370-10375.
23. Watanabe, M., Sasaki, M., Itoh, K., Higashihara, M., Umezawa, K., Kadin, M.E., Abraham, L.J., Watanabe, T. & Horie, R. (2005) JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Research, 65, 7628-7634.
24. Watanabe, M., Itoh, K., Togano, T., Kadin, M.E., Watanabe, T., Higashihara, M. & Horie, R. (2012) Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma. American Journal of Pathology, 180, 831-838.
25. Weiss, L.M., Lopategui, J.R., Sun, L.H., Kamel, O.W., Koo, C.H. & Glackin, C. (1995) Absence of the t(2;5) in Hodgkin's disease. Blood, 85, 2845-2847.
26. Zamo, A., Chiarle, R., Piva, R., Howes, J., Fan, Y., Chilosi, M., Levy, D.E. & Inghirami, G. (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 21, 1038-1047.